Alan Bilsland

Author PubWeight™ 8.20^‹?›

Rank	Title	Journal	Year	PubWeight™‹?›
1	A mutation in a functional Sp1 binding site of the telomerase RNA gene (hTERC) promoter in a patient with Paroxysmal Nocturnal Haemoglobinuria.	BMC Blood Disord	2004	1.05
2	Involvement of NF-Y and Sp1 binding sequences in basal transcription of the human telomerase RNA gene.	FEBS Lett	2003	1.02
3	Synthetic anticancer gene medicine exploits intrinsic antitumor activity of cationic vector to cure established tumors.	Cancer Res	2005	0.96
4	Scoring of senescence signalling in multiple human tumour gene expression datasets, identification of a correlation between senescence score and drug toxicity in the NCI60 panel and a pro-inflammatory signature correlating with survival advantage in peritoneal mesothelioma.	BMC Genomics	2010	0.94
5	TCEAL7 inhibition of c-Myc activity in alternative lengthening of telomeres regulates hTERT expression.	Neoplasia	2010	0.90
6	Drug insight: Cancer cell immortality-telomerase as a target for novel cancer gene therapies.	Nat Clin Pract Oncol	2004	0.89
7	MDM2 negatively regulates the human telomerase RNA gene promoter.	BMC Cancer	2005	0.87
8	Telomerase-directed molecular therapeutics.	Expert Rev Mol Med	2002	0.82
9	Modulation of gene expression using zinc finger-based artificial transcription factors.	Methods Mol Biol	2010	0.79
10	Investigating Various Thresholds as Immunohistochemistry Cutoffs for Observer Agreement.	Appl Immunohistochem Mol Morphol	2016	0.75